This post was originally published on this site is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to

Jorge CondeAndreessen Horowitz general partner Jorge Conde Andreessen Horowitz

  • Silicon Valley venture firm Andreessen Horowitz is launching a second fund that will focus on biology, investing $450 million. 
  • This one, building on the experience a16z has had with its first biofund, which launched in 2015 with $200 million, will focus on the intersection of biology and engineering. 
  • The fund will focus on investing in companies applying engineering to things like drug discovery, creating new uses for biology, and finding new ways for software to “eat” healthcare. 

The venture capital firm with a tagline that “software is eating the world” thinks the same could happen with biology.

On Thursday, Andreessen Horowitz launched its second bio-focused fund to invest $450 million in companies that sit at the intersection of biology and engineering. 

It’s the second bio-fund Andreessen Horowitz has done. In 2015, it launched a fund with $200 million to invest in companies that were focused on biology and computer science. 

Andreessen Horowitz general partner Jorge Conde, who will be leading the fund with Vijay Pande, said that the second fund’s approach to focus on engineering more broadly happened because the firm saw opportunities that extended beyond just computer science. 

“We’re at the precipice of bio becoming a part and a transformative part of not just healthcare, but across many industries,” Conde told Business Insider. “Whether it’s energy or food or consumer products, that to us is an extraordinarily exciting moment and area for us to pursue.”

The fund will focus in on three areas where engineering and biology are coming together. 

  • Computational biology, and how machine learning and artificial intelligence can apply to biology.  It’s an area a16z’s already invested in with companies like Freenome, a company developing a test to look for signs of cancer in the body, and twoXAR, a company using machine learning to help with drug discovery. 
  • New ways to use biology, either by reading genetic information, writing it out to make changes to organisms, or by programming organisms to take on a task. These new uses could be things like gene editing, building synthetic DNA, or reprogramming cells to fight certain diseases like the cell therapies being used in cancer.
  • Finding companies building software that “eats” healthcare, especially by creating marketplaces.

At L Technology Group, we know technology alone will not protect us from the risks associated with in cyberspace. Hackers, Nation States like Russia and China along with “Bob” in HR opening that email, are all real threats to your organization. Defending against these threats requires a new strategy that incorporates not only technology, but also intelligent personnel who, eats and breaths cybersecurity. Together with proven processes and techniques combines for an advanced next-generation security solution. Since 2008 L Technology Group has develop people, processes and technology to combat the ever changing threat landscape that businesses face day to day.

Call Toll Free (855) 999-6425 for a FREE Consultation from L Technology Group,